Belite Bio Inc. (NASDAQ:BLTE) shares are sinking Friday after the FDA added three months to its review timeline of the company’s application for tinlarebant. Here’s what you should know.
- Belite Bio shares are retreating from recent levels. Why is BLTE stock dropping?
Belite Bio Stock Falls as FDA Extends Tinlarebant Review
Tinlarebant is the Belite Bio candidate aimed at Stargardt disease type 1, and its New Drug Application is under FDA review. Belite Bio is a clinical-stage company that develops treatments for degenerative retinal diseases.
On Friday, the company disclosed that the FDA had added three months to that review. The new Prescription Drug User Fee Act action date is May 12, 2027.
The agency wants more time to study data submitted with the filing, Belite Bio said. If the review reveals no major problems, the FDA intends to send labeling suggestions and any follow-up commitments it expects after launch by April 12, 2027.
Belite Bio said it plans to keep collaborating closely with regulators and still believes its clinical data support tinlarebant in Stargardt disease type 1 patients.
A three-month delay could push back both the drug’s arrival for patients and any revenue for Belite Bio.
Belite Bio Stock Technical Read: Breakdown Below $130
BLTE has lost support that had held for about six months. After rising from $130.00 on June 2 to $198.58 on Sept. 8, it gave back the entire advance and sits at $129.50, a multi-month low that also falls under the 200-day average.
Other indicators lean the same way. Price sits under the 20-day, 50-day and 200-day moving averages, and the 50-day slipped beneath the 200-day Nov. 17. MACD is negative and below its signal line.
Closing above $130.00 would negate the breakdown. A gap near $151.02, Thursday’s close, could be a second area worth watching.
BLTE Shares Are Tumbling
BLTE Price Action: Belite Bio shares were down 13.85% at $130.10 at the time of publication on Friday, according to Benzinga Pro.
Image: Sandinashr/Shutterstock
Recent Comments